Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Research Clears Paths to Improved Arthritis Patient Care, Long-Term Health

Susan Bernstein  |  Issue: February 2017  |  February 15, 2017

Various-Everythings/shutterstock.com

Various-Everythings/shutterstock.com

WASHINGTON, D.C.—Rheumatology researchers look for next-generation treatments, healthy interventions, and genetic and microbial clues to disease pathogenesis and therapy response, according to new studies presented at a Nov. 15, 2016, press conference at the 2016 ACR/ARHP Annual Meeting.

OA & Physical Function

How do you know when a patient with knee osteoarthritis (OA) has the ability to walk at least 6,000 steps a day, an established benchmark for good physical function? That was the focus of a new study presented by its co-author, Daniel K. White, PT, ScD, MSc, assistant professor of physical therapy at the University of Delaware.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Physical activity is incredibly important for health, especially for people with knee osteoarthritis,” said Mr. White. “Currently, we don’t know how much physical capacity you need to have to be physically active or to walk 6,000 steps per day.”

Mr. White and his colleagues used data on 1,790 knee OA patients taken from the Osteoarthritis Initiative (OAI) to measure physical activity and function using three tests: how long it takes a patient to stand up from a chair five times, how long it takes them to walk 400 meters and their speed on a 20-meter walk. From these data, they determined function thresholds for patients to be able to walk 6,000 steps daily: taking 12 seconds or less to get up and down from a chair five times, walking 400 meters in 5.5 minutes or less, or walking slower than 1.2 meters per second, Mr. White said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The good news: More than two-thirds of the patients met or exceeded these thresholds. Patients who don’t meet these thresholds may have levels of physical function too low to be able to walk 6,000 daily steps and need to be referred to rehabilitation, he said. Tests like timing a patient getting up from a chair five times is something that all physicians can do in their offices. “Some physicians [may] be nervous about getting a patient out in the hallway to time them walking, but getting up from a chair is pretty failsafe,” he said.

Microbial Clues

Fecal matter of people with antiphospholipid syndrome (APS), an autoimmune disorder associated with higher thrombosis risk, is enriched with particular, phospholipid-producing bacteria, a new study found.2

Emerging literature suggests that microbiota in patients’ guts may interact with the immune system, and the study suggests that these microbes may be involved in APS pathogenesis, said Martin A. Kriegel, MD, PhD, the principal investigator and assistant professor of immunobiology and medicine at Yale School of Medicine in New Haven, Conn.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Meeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingOutcomesPathogenesispatient careResearchRheumatic DiseaserheumatologystudiestherapyTreatment

Related Articles

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

    Antiphospholipid Antibody Testing Update

    January 13, 2012

    Successes, challenges, and controversies of diagnostic methods for APS

    Put Hughes Syndrome on Your Radar

    April 1, 2007

    Diagnosis of antiphospholipid syndrome is increasing. Here’s how to recognize and treat it

    A Catalyst for Antiphospholipid Syndrome Research

    March 18, 2011

    APS ACTION is coordinating international efforts to study this rare and potentially fatal autoimmune disorder

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences